Selected research
Industry Research
Bispecific Antibody Drug Industry Research Report 2026
Market perspective
The global Bispecific Antibody Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Bispecific Antibody Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Bispecific Antibody Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Bispecific Antibody Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Bispecific Antibody Drug include Affimed, Akeso, Alphamab, BeiGene, Genmab, Immunocore Limited, Lindis Biotech, MacroGenics and Xencor, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Bispecific Antibody Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Bispecific Antibody Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bispecific Antibody Drug Market by Company
Affimed
Akeso
Alphamab
BeiGene
Genmab
Immunocore Limited
Lindis Biotech
MacroGenics
Xencor
AstraZeneca
Abbvie
Amgen
Pfizer
Roche
Merck
Johnson & Johnson
Sanofi
Bispecific Antibody Drug Segment by Type
Fragment-Based
IgG-Based
Bispecific Antibody Drug Segment by Application
Cancer
Haemophilia
Other Diseases
Bispecific Antibody Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bispecific Antibody Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bispecific Antibody Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bispecific Antibody Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Bispecific Antibody Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Fragment-Based
- IgG-Based
Applications
- Cancer
- Haemophilia
- Other Diseases
Companies covered
- Affimed
- Akeso
- Alphamab
- BeiGene
- Genmab
- Immunocore Limited
- Lindis Biotech
- MacroGenics
- Xencor
- AstraZeneca
- Abbvie
- Amgen
- Pfizer
- Roche
- Merck
- Johnson & Johnson
- Sanofi
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Bispecific Antibody Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Fragment-Based
- 2.2.3 IgG-Based
- 2.3 Bispecific Antibody Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cancer
- 2.3.3 Haemophilia
- 2.3.4 Other Diseases
- 2.4 Assumptions and Limitations
3 Bispecific Antibody Drug Breakdown Data by Type
- 3.1 Global Bispecific Antibody Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Bispecific Antibody Drug Forecasted Market Size by Type (2027-2032)
4 Bispecific Antibody Drug Breakdown Data by Application
- 4.1 Global Bispecific Antibody Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Bispecific Antibody Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Bispecific Antibody Drug Market Perspective (2021-2032)
- 5.2 Global Bispecific Antibody Drug Growth Trends by Region
- 5.2.1 Global Bispecific Antibody Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Bispecific Antibody Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Bispecific Antibody Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Bispecific Antibody Drug Market Dynamics
- 5.3.1 Bispecific Antibody Drug Industry Trends
- 5.3.2 Bispecific Antibody Drug Market Drivers
- 5.3.3 Bispecific Antibody Drug Market Challenges
- 5.3.4 Bispecific Antibody Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Bispecific Antibody Drug Players by Revenue
- 6.1.1 Global Top Bispecific Antibody Drug Players by Revenue (2021-2026)
- 6.1.2 Global Bispecific Antibody Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Bispecific Antibody Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Bispecific Antibody Drug Head Office and Area Served
- 6.4 Global Bispecific Antibody Drug Players, Product Type & Application
- 6.5 Global Bispecific Antibody Drug Manufacturers Established Date
- 6.6 Global Bispecific Antibody Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Bispecific Antibody Drug Market Size (2021-2032)
- 7.2 North America Bispecific Antibody Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Bispecific Antibody Drug Market Size by Country (2021-2026)
- 7.4 North America Bispecific Antibody Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Bispecific Antibody Drug Market Size (2021-2032)
- 8.2 Europe Bispecific Antibody Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Bispecific Antibody Drug Market Size by Country (2021-2026)
- 8.4 Europe Bispecific Antibody Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Bispecific Antibody Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Bispecific Antibody Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Bispecific Antibody Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Bispecific Antibody Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Bispecific Antibody Drug Market Size (2021-2032)
- 10.2 South America Bispecific Antibody Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Bispecific Antibody Drug Market Size by Country (2021-2026)
- 10.4 South America Bispecific Antibody Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Bispecific Antibody Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Bispecific Antibody Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Bispecific Antibody Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Bispecific Antibody Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Affimed
- 12.1.1 Affimed Company Information
- 12.1.2 Affimed Business Overview
- 12.1.3 Affimed Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.1.4 Affimed Bispecific Antibody Drug Product Portfolio
- 12.1.5 Affimed Recent Developments
- 12.2 Akeso
- 12.2.1 Akeso Company Information
- 12.2.2 Akeso Business Overview
- 12.2.3 Akeso Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.2.4 Akeso Bispecific Antibody Drug Product Portfolio
- 12.2.5 Akeso Recent Developments
- 12.3 Alphamab
- 12.3.1 Alphamab Company Information
- 12.3.2 Alphamab Business Overview
- 12.3.3 Alphamab Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.3.4 Alphamab Bispecific Antibody Drug Product Portfolio
- 12.3.5 Alphamab Recent Developments
- 12.4 BeiGene
- 12.4.1 BeiGene Company Information
- 12.4.2 BeiGene Business Overview
- 12.4.3 BeiGene Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.4.4 BeiGene Bispecific Antibody Drug Product Portfolio
- 12.4.5 BeiGene Recent Developments
- 12.5 Genmab
- 12.5.1 Genmab Company Information
- 12.5.2 Genmab Business Overview
- 12.5.3 Genmab Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.5.4 Genmab Bispecific Antibody Drug Product Portfolio
- 12.5.5 Genmab Recent Developments
- 12.6 Immunocore Limited
- 12.6.1 Immunocore Limited Company Information
- 12.6.2 Immunocore Limited Business Overview
- 12.6.3 Immunocore Limited Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.6.4 Immunocore Limited Bispecific Antibody Drug Product Portfolio
- 12.6.5 Immunocore Limited Recent Developments
- 12.7 Lindis Biotech
- 12.7.1 Lindis Biotech Company Information
- 12.7.2 Lindis Biotech Business Overview
- 12.7.3 Lindis Biotech Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.7.4 Lindis Biotech Bispecific Antibody Drug Product Portfolio
- 12.7.5 Lindis Biotech Recent Developments
- 12.8 MacroGenics
- 12.8.1 MacroGenics Company Information
- 12.8.2 MacroGenics Business Overview
- 12.8.3 MacroGenics Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.8.4 MacroGenics Bispecific Antibody Drug Product Portfolio
- 12.8.5 MacroGenics Recent Developments
- 12.9 Xencor
- 12.9.1 Xencor Company Information
- 12.9.2 Xencor Business Overview
- 12.9.3 Xencor Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.9.4 Xencor Bispecific Antibody Drug Product Portfolio
- 12.9.5 Xencor Recent Developments
- 12.10 AstraZeneca
- 12.10.1 AstraZeneca Company Information
- 12.10.2 AstraZeneca Business Overview
- 12.10.3 AstraZeneca Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.10.4 AstraZeneca Bispecific Antibody Drug Product Portfolio
- 12.10.5 AstraZeneca Recent Developments
- 12.11 Abbvie
- 12.11.1 Abbvie Company Information
- 12.11.2 Abbvie Business Overview
- 12.11.3 Abbvie Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.11.4 Abbvie Bispecific Antibody Drug Product Portfolio
- 12.11.5 Abbvie Recent Developments
- 12.12 Amgen
- 12.12.1 Amgen Company Information
- 12.12.2 Amgen Business Overview
- 12.12.3 Amgen Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.12.4 Amgen Bispecific Antibody Drug Product Portfolio
- 12.12.5 Amgen Recent Developments
- 12.13 Pfizer
- 12.13.1 Pfizer Company Information
- 12.13.2 Pfizer Business Overview
- 12.13.3 Pfizer Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.13.4 Pfizer Bispecific Antibody Drug Product Portfolio
- 12.13.5 Pfizer Recent Developments
- 12.14 Roche
- 12.14.1 Roche Company Information
- 12.14.2 Roche Business Overview
- 12.14.3 Roche Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.14.4 Roche Bispecific Antibody Drug Product Portfolio
- 12.14.5 Roche Recent Developments
- 12.15 Merck
- 12.15.1 Merck Company Information
- 12.15.2 Merck Business Overview
- 12.15.3 Merck Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.15.4 Merck Bispecific Antibody Drug Product Portfolio
- 12.15.5 Merck Recent Developments
- 12.16 Johnson & Johnson
- 12.16.1 Johnson & Johnson Company Information
- 12.16.2 Johnson & Johnson Business Overview
- 12.16.3 Johnson & Johnson Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.16.4 Johnson & Johnson Bispecific Antibody Drug Product Portfolio
- 12.16.5 Johnson & Johnson Recent Developments
- 12.17 Sanofi
- 12.17.1 Sanofi Company Information
- 12.17.2 Sanofi Business Overview
- 12.17.3 Sanofi Revenue in Bispecific Antibody Drug Business (2021-2026)
- 12.17.4 Sanofi Bispecific Antibody Drug Product Portfolio
- 12.17.5 Sanofi Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst